Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $2.4 million.

  • Biofrontera's Other Operating Expenses fell 5151.7% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year decrease of 2049.16%. This contributed to the annual value of $36.2 million for FY2024, which is 528.78% down from last year.
  • Latest data reveals that Biofrontera reported Other Operating Expenses of $2.4 million as of Q3 2025, which was down 5151.7% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Other Operating Expenses ranged from a high of $25.8 million in Q4 2023 and a low of $196000.0 during Q3 2022
  • Its 5-year average for Other Operating Expenses is $5.6 million, with a median of $3.8 million in 2021.
  • Per our database at Business Quant, Biofrontera's Other Operating Expenses plummeted by 9377.78% in 2022 and then soared by 238163.27% in 2023.
  • Biofrontera's Other Operating Expenses (Quarter) stood at $1.8 million in 2021, then skyrocketed by 206.86% to $5.7 million in 2022, then surged by 354.69% to $25.8 million in 2023, then decreased by 11.68% to $22.8 million in 2024, then tumbled by 89.63% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.7 million for Q2 2025, and $3.3 million during Q1 2025.